,Canonical_Smiles,drug_name,drug_type,Label
0,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2C19-Inhibitor,positive
1,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
2,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,2C19-Inhibitor,positive
3,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
4,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
5,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,Levodopa,Methyltransferase-Substrate,negative
6,NC(N)=O,Carbamide,2E1-Inducer,negative
7,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,Ibuprofen,GST-Inducer,negative
8,Oc1ccccc1,Phenol,2E1-Substrate,negative
9,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
10,CCCC1(CCc2ccccc2)CC(O)=C(C(CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,Tipranavir,-,negative
11,CN(C)C(=N)NC(=N)N,Metformin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
12,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,Zotepine,2D6-Substrate,negative
13,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O)O[C@H](CO)[C@H]4O)O[C@H](CO)[C@H]3O)O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Lentinan,GST-Inhibitor,negative
14,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,2C19-Inhibitor,positive
15,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminoglutethimide,-,negative
16,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
17,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,Calcitriol,SUL-Inducer,negative
18,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
19,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,GST-Inhibitor,negative
20,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
21,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
22,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,Teicoplanin,SUL-Substrate,negative
23,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,Pentamidine Isethionate,2D6-Substrate,negative
24,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
25,CC(C)NC[C@H]1CCc2cc(CO)c([N+](=O)[O-])cc2N1,Oxamniquine,2D6-Inhibitor,negative
26,Cc1cc(=O)oc2cc(O)ccc12,Hymecromone,UGT-Inhibitor,negative
27,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
28,Cc1cc(NC(=O)NC(=O)c2ccccc2N(C)C)ccc1Oc1ncc(Br)cn1,benzoyl_phenyl_urea,2D6-Substrate,negative
29,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,Ergotamine,-,negative
30,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2C19-Inhibitor,positive
31,CCN(CC)CCNC(=O)c1ccc(N)cc1,Procainamide,2D6-Substrate,negative
32,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,2C19-Inhibitor,positive
33,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
34,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
35,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
36,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,Prazosin,Solute_carrier_family_22_member_1-Inhibitor,negative
37,O=C(O)CCCC[C@@H]1SC[C@H]2NC(=O)N[C@H]21,Biotin,1B1-Inducer,negative
38,CN1CCC23CCCCC2C1Cc1ccc(O)cc13,Dextrorphan,2D6-Substrate,negative
39,COc1ccc2c(c1)[nH]c1c(C)nccc12,harmine,2D6-Substrate,negative
40,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
41,c1ccc(C2(c3ccccc3)C[C@H]2C2=NCCN2)cc1,Cibenzoline,2D6-Substrate,negative
42,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
43,c1ccccc1,Benzene,-,negative
44,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
45,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Diclofenac,CP2CI-Substrate,negative
46,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
47,C/C=C\C,cis_2_butene,2E1-Substrate,negative
48,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,Reserpine,-,negative
49,Cc1ccsc1-c1ccc([C@H](C)C(=O)O)cc1,S_MTPPA,2C9-Substrate,negative
50,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
51,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,Mifepristone,P450_HFLA-Inhibitor,negative
52,CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],Pyridostigmine bromide,-,negative
53,O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,rutaecarpine,2E1-Substrate,negative
54,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
55,CC1=CC(=O)C=C2CCC3C4CCC(=O)C4(C)CCC3C12C,Atamestane,-,negative
56,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,Sulpiride,-,negative
57,C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor,negative
58,CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,Maprotiline,2D6-Substrate,negative
59,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,Quetiapine,P450_HFLA-Substrate,negative
60,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
61,CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc(S(C)=O)cc1,Sulindac,GST-Inducer,negative
62,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
63,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2,2_acetylamino_fluorene,1A2-Substrate,negative
64,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
65,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
66,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,Loperamide,2D6-Substrate,negative
67,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
68,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,Betamethasone,-,negative
69,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
70,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,Epirubicin,Multidrug_resistance_associated_protein_1-Inducer,negative
71,CCCCN(CCCC)CC[C@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,Halofantrine,2D6-Inhibitor,negative
72,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,Amodiaquine,2D6-Inhibitor,negative
73,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,Teriparatide,24A-Inhibitor,negative
74,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
75,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
76,COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,3_methylether_estradiol,2C19-Substrate,negative
77,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],Dipotassium clorazepate,-,negative
78,Cc1ccc(C)cc1,xylene_para,2E1-Substrate,negative
79,CN1C2CCC1CC(NC(=O)c1cc(Cl)cc3c1OC(C)(C)C3)C2,Zatosetron,-,negative
80,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,cerivastatin,3A4-Substrate,negative
81,CC=O,acetaldehyde,2E1-Substrate,negative
82,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
83,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
84,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,-,negative
85,Cc1cc(N(C)C)ccc1CC(C)N,Amiflamine,2D6-Substrate,negative
86,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
87,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,Cinacalcet,2D6-Substrate,negative
88,N#Cc1ccc(C2CCCc3cncn32)cc1,Fadrozole,-,negative
89,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
90,CC(=O)Nc1ccccc1,Acetanilide,-,negative
91,C#CC1(O)CCC2C3CCc4cc(OC)ccc4C3CCC21C,Mestranol,-,negative
92,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
93,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
94,Cc1cc2c3ccccc3ccc2c2ccccc12,6_methylchrysene,2E1-Substrate,negative
95,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
96,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,Pregnenolone,2D6-Substrate,negative
97,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
98,Nc1ccc(O)c(C(=O)O)c1,Mesalazine,Methyltransferase-Inhibitor,negative
99,CC[C@@]1(c2ccccc2)NC(=O)N(C)C1=O,Mephenytoin,2C19-Inhibitor,positive
100,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
101,C=CC[C@@H]1C=C(C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](C(C)=C[C@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Tacrolimus,P450_HFLA-Substrate,negative
102,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
103,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
104,Cc1ccc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)nc1,Glipizide,-,negative
105,Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@@H]5C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@@H]3C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]2C)c(N)c1=O,Dactinomycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
106,CCO,Ethanol,2C19-Inhibitor,positive
107,CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1,Salbutamol,-,negative
108,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,-,negative
109,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
110,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
111,Cc1c2ccccc2c(C)c2c1ccc1ccccc12,DMBA,2E1-Substrate,negative
112,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
113,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
114,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,Sorafenib,UGT-Inhibitor,negative
115,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,Isosorbide Mononitrate,3A4-Substrate,negative
116,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Quinine,-,negative
117,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
118,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
119,CCOc1ccc2ccc(=O)oc2c1,7_ethoxy_coumarin,2E1-Substrate,negative
120,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
121,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
122,CCC(=O)O[C@@H](O[P@@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate,negative
123,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
124,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
125,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
126,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,positive
127,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,2C19-Inhibitor,positive
128,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
129,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,Technetium (99mTc) Mebrofenin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
130,CC(=O)c1cc2cccc(OC[C@H](O)CNC(C)C)c2o1,Befunolol,2D6-Substrate,negative
131,CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1,Gepirone,2D6-Substrate,negative
132,CN1C(=O)[C@H](O)N=C(c2ccccc2)c2cc(Cl)ccc21,Temazepam,-,negative
133,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,Sertraline,2C19-Inhibitor,positive
134,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
135,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
136,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,Phenylbutazone,-,negative
137,COc1cc2c(CCN3CCN(c4cccc(Cl)c4C)CC3)nn(Cc3c[nH]cn3)c2cc1OC,DY_9760e,2D6-Substrate,negative
138,CO[C@@H](CNC(=O)c1ccccc1OCC(=O)[O-])C[Hg]O,Sodium Salicylate,2E1-Inducer,negative
139,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
140,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
141,CCc1cccc2cc(C(O)CNC(C)(C)C)oc12,Bufuralol,2D6-Substrate,negative
142,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,2D6-Substrate,negative
143,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
144,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
145,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
146,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,Minaprine,2D6-Substrate,negative
147,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,Indometacin,2C19-Inhibitor,positive
148,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
149,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
150,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,Amoxapine,2D6-Substrate,negative
151,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
152,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
153,CCOC(=O)c1ccc(N)cc1,Benzocaine,2E1-Inhibitor,negative
154,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
155,Cc1cccc(Nc2ccccc2C(=O)O)c1C,Mefenamic acid,-,negative
156,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,Oxymetazoline,UGT-Substrate,negative
157,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
158,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,budesonide,3A4-Substrate,negative
159,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Cetirizine,-,negative
160,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
161,O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12,Cefaloridine,2C8-Substrate,negative
162,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
163,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
164,CCOc1ccc2nc3ccc(=O)cc-3oc2c1,7_ethoxy_resorufin,1A2-Substrate,negative
165,CCCCCCCCC,nonane,2E1-Substrate,negative
166,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,Cefaclor,Solute_carrier_family_22_member_6-Inhibitor,negative
167,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
168,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
169,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
170,CN(C)CCO,Deanol,Methyltransferase-Substrate,negative
171,CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,etodolac_R,2C9-Substrate,negative
172,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
173,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
174,O=Cc1c2ccccc2cc2ccccc12,9_anthraldehyde,2E1-Substrate,negative
175,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,Diosmectite,1B1-Inhibitor,negative
176,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
177,NC(=O)NO,Hydroxycarbamide,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
178,CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Amifloxacin,-,negative
179,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,Ganciclovir,Neutral_amino_acid_transporter_B0-Substrate,negative
180,Cc1ccc(C(=O)[C@H](C)CN2CCCCC2)cc1,Tolperisone,2D6-Substrate,negative
181,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
182,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Tobramycin,N_acetyltransferase-Substrate,negative
183,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
184,COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,DDB_aka_BDD,2C9-Substrate,negative
185,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide,-,negative
186,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Papaverine,2D6-Substrate,negative
187,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Prochlorperazine,2D6-Substrate,negative
188,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,Haloperidol,P450_HFLA-Substrate,negative
189,CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2,thioridazine_R,2E1-Substrate,negative
190,CC1(C)O[C@H]2CO[C@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@H]2O1,Topiramate,2C19-Inhibitor,positive
191,CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O,tauromustine,2D6-Substrate,negative
192,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,Physostigmine,Methyltransferase-Inhibitor,negative
193,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
194,COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1,Fluvoxamine,2C19-Inhibitor,positive
195,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@H]3SC(=O)NC3=O)cc1)O2,troglitazone,2C8-Substrate,negative
196,O[C@H](CBr)[C@@H](O)[C@H](O)[C@H](O)CBr,Mitobronitol,1B1-Inducer,negative
197,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
198,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
199,CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3C[C@H](O)[C@]12C,5beta_cholestane_3alpha_7alpha_12alpha_triol,2C19-Substrate,negative
200,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
201,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
202,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
203,CC(N)C(=O)c1ccccc1,Cathinone,-,negative
204,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
205,CC1=CC(=O)c2ccccc2C1=O,Menadione,2E1-Substrate,negative
206,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
207,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Chlormadinone,2C19-Inhibitor,positive
208,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
209,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
210,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
211,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
212,OCCOCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Hydroxyzine,2D6-Inhibitor,negative
213,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
214,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
215,O[C@@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2,Biperiden,2D6-Inhibitor,negative
216,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
217,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
218,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
219,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
220,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
221,Cn1cc[nH]c1=S,Thiamazole,2C19-Inhibitor,positive
222,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
223,N[C@@H]1CCCC[C@H]1N,Oxaliplatin,2E1-Substrate,negative
224,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
225,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
226,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
227,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2C19-Inhibitor,positive
228,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12,Corticosterone,-,negative
